Company to Appeal Preliminary Decision
- NeoGenomics shares fall 11% after preliminary patent-infringement ruling
- Company plans to appeal the ruling
- Shares have more than doubled this year
Shares of NeoGenomics dropped 11% after the company announced its intention to appeal a preliminary ruling in a patent-infringement lawsuit filed by Natera. The ruling, issued by a North Carolina district court, prohibits NeoGenomics from selling its RaDaR technology. NeoGenomics, a Florida-based oncology testing services company, expressed its commitment to bringing its highly sensitive test to market and providing cancer patients and clinicians with more options for care. Despite the setback, NeoGenomics’ shares have more than doubled this year.
Public Companies: NeoGenomics (unknown), Natera (unknown)
Private Companies:
Key People: Chris Smith (Chief Executive)
Factuality Level: 7
Justification: The article provides factual information about NeoGenomics appealing a preliminary ruling in a patent-infringement lawsuit brought by Natera. It includes direct quotes from NeoGenomics’ Chief Executive and mentions the stock price decline. However, the article lacks in-depth analysis and context about the lawsuit and the companies involved.
Noise Level: 3
Justification: The article provides a brief overview of the situation, but lacks in-depth analysis or evidence to support the claims made. It does not explore the consequences of the ruling or provide any actionable insights.
Financial Relevance: Yes
Financial Markets Impacted: Shares of NeoGenomics
Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: The article pertains to a financial topic as it discusses the impact of a patent-infringement lawsuit on NeoGenomics’ stock. However, there is no mention of an extreme event or its impact.
www.marketwatch.com 
